Sep 09, 2019 / 05:00PM GMT
Presentation
Sep 09, 2019 / 05:00PM GMT
=====================
Corporate Participants
=====================
* Anne E. White
Eli Lilly and Company - Senior VP & President of Lilly Oncology
* Daniel M. Skovronsky
Eli Lilly and Company - Senior VP & Chief Scientific Officer
* Jacob S. Van Naarden
Loxo Oncology, Inc. - COO
* Kevin Hern
Eli Lilly and Company - VP of IR
* S. Michael Rothenberg
Loxo Oncology, Inc. - VP of Research and Development.
=====================
Conference Call Participants
=====================
* Christopher Thomas Schott
JP Morgan Chase & Co, Research Division - Senior Analyst
* Jason Matthew Gerberry
BofA Merrill Lynch, Research Division - MD in US Equity Research
* Louise Alesandra Chen
Cantor Fitzgerald & Co., Research Division - Senior Research Analyst & MD
* Navin Cyriac Jacob
UBS Investment Bank, Research Division - Equity Research Analyst of Specialty Pharmaceuticals and Large Cap Pharmaceutic
Eli Lilly and Co
(MIL:1LLY)
€
1,037.4
-22.4 (-2.11%)
Market Cap: 930.72 Bil
Enterprise Value: 964.17 Bil
PE Ratio: 42.22
PB Ratio: 34.04
GF Score: 76/100 Eli Lilly and Co to Discuss World Conference on Lung Cancer Presentation Transcript
Sep 09, 2019 / 05:00PM GMT
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |

30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot